

## Antibodies to Hepatitis B core antigen prevalence study in Kazakhstan

Tatyana Savchuk<sup>1</sup>, Yelena Grinvald<sup>1</sup>, Mohamed Ali<sup>2</sup>, Ramune Sepetiene<sup>3</sup>, Saniya Saussakova<sup>1,4</sup>, Kuralay Zhangazieva<sup>1</sup>, Dulat Imashpayev<sup>1</sup>, Saniya Abdrakhmanova<sup>1</sup>

<sup>1</sup> Scientific-Production Center of Transfusiology, Nur-Sultan, Kazakhstan

<sup>2</sup> Abbott Laboratories GmbH, DAFZA, P.O. Box 32002, Dubai, UAE

<sup>3</sup> Abbott GmbH Max-Planck-Ring 2, 65205, Wiesbaden, Germany,

[ramune.sepetiene@abbott.com](mailto:ramune.sepetiene@abbott.com)

<sup>4</sup> Astana Medical University, Nur-Sultan, Kazakhstan

### Information about authors

<sup>1</sup>**Tatyana N. Savchuk** - Head of the Republican Reference Laboratory, Scientific-Production Center of Transfusiology, Nur-Sultan, Kazakhstan, [tanyusha\\_astana@mail.ru](mailto:tanyusha_astana@mail.ru)

<sup>1</sup>**Yelena N. Grinvald** - Head of the Department of Laboratory Research of Transfusion Infections, Scientific-Production Center of Transfusiology, Nur-Sultan, Kazakhstan, [lena161983@mail.ru](mailto:lena161983@mail.ru)

<sup>2</sup>**Mohamed Ali** - Abbott Laboratories GmbH, DAFZA, P.O. Box 32002, Dubai, UAE, [mohamed.ali@abbott.com](mailto:mohamed.ali@abbott.com)

<sup>3</sup>**Ramune Sepetiene** - Abbott GmbH Max-Planck-Ring 2, 65205, Wiesbaden, Germany, [ramune.sepetiene@abbott.com](mailto:ramune.sepetiene@abbott.com)

<sup>1,4</sup>**Saniya B. Saussakova** - Research Management Department Manager, Scientific-Production Center of Transfusiology; PhD student, Department of Public Health, Astana Medical University, Nur-Sultan, Kazakhstan, [saussakova.s@gmail.com](mailto:saussakova.s@gmail.com)

<sup>1</sup>**Kuralay K. Zhangazieva** - Head of the Research Management Department, Scientific-Production Center of Transfusiology, [zhangazieva@mail.ru](mailto:zhangazieva@mail.ru)

<sup>1</sup>**Dulat M. Imashpayev** - First Deputy Chairman of the Board, Scientific-Production Center of Transfusiology, [imashpayev@mail.ru](mailto:imashpayev@mail.ru)

<sup>1</sup>**Saniya A. Abdrakhmanova** - Chairman of the Board, Scientific-Production Center of Transfusiology, [a.saniya@mail.ru](mailto:a.saniya@mail.ru)

**Declaration of conflicting interests:** The authors declare that there is no conflict of interest in the present study.

**Funding.** This research was supported by a grant from Abbott Laboratories, Chicago.

**Author contribution statement:** All authors were equally involved.

## **ABSTRACT**

### Background

Kazakhstan is being considered as one of the countries that is medium-endemic for Hepatitis B virus infection. This cross-sectional study aimed to evaluate the prevalence of anti-HBcore and the risk factors impacting positive anti-HBcore markers among donors at Scientific-Production Center of Transfusiology, of the Kazakhstan Republic.

### Study Design and Methods

The samples taken from blood donors were tested for anti-HBcore, by CLIA on the Architect i2000SR (ABBOTT). In case of positive anti-HBcore, the blood samples were further tested for anti-HBs by CLIA on the Architect i2000SR (ABBOTT). Statistical analysis was conducted by the R software (version 4.1.1, USA, 2021).

### Results and Discussion

5709 people aged 18 to 66 years included in the study, the proportion of men and women was 68.17% and 31.83%. The average age of the participants was  $35.7 \pm 10.57$  years.

The prevalence of anti-HBcore among donors was 17.2% (983). Among participants with elevated ALT (170) this marker was determined in 23%, and in donors with normal levels of ALT (5539) - 17%. Participants with positive anti-HBcore scores were on average older (41.8 vs 34.4 years,  $p < 0.001$ ) and Kazakh (88.7% vs 83.0%,  $p < 0.001$ ) by Nationality than study participants with negative results respectively. Anti-HBcore (Antibodies to Hepatitis B core antigen) prevalence in Kazakhstan (17.2%) compared to other countries (8% and more) remains above average. Given the prevalence of HBV and risk factors, it is recommended to include an additional anti-HBcore marker in the mandatory screening of donated blood in the country and improve preventive measures to HBV transmission.

## **INTRODUCTION**

Hepatitis B (HBV) is a contagious liver disease that results from infection with the Hepatitis B virus. The World Health Organization (WHO) estimated that approximately 2 billion people are

carriers of HBV worldwide [1]. Results of epidemiological studies have shown that about 240 million patients have chronic hepatitis B infection (CHB) [2-3].

HBV remains the infection transmissible by direct exposure to infected blood or organic fluids. The existing risk of transmission of HBV is associated with transfusion of blood taken from infected individuals during the window phase and presence of occult HBV [4-7]. High risk of transfusion infection stimulates the realization of the measures for increasing the safety of blood [8].

HBV screening programs often only test for Hepatitis B surface antigen (HBsAg) and antibody to Hepatitis B surface antigen (anti-HBs), not counting those people in whom antibody to hepatitis B core antigen is a positive marker.

Anti-HBcore is produced in infected individuals, both in chronic carrier state and at the end of an acute resolving infection [9]. Also, it is considered an effective marker for occult HBV infection and is an integral part of blood donor screening in many countries.

Alanine aminotransferase (ALT) is a surrogate marker for viral hepatitis. Anti-HBc and ALT tests have been used in Brazil since 1993 [10] and Hungary since 2006 [11]. Results of a 10-year surveillance programme in Germany [12] showed that anti-HBc screening introduced in 2006 has improved blood safety in the country. Study in Netherlands [13] showed similar results. Since 2011 anti-HBc testing has enhanced the safety of the Dutch blood supply but its exact yield remains difficult to determine, due to the complexity of confirming anti-HBc reactivity and occult hepatitis B infection (OBI).

The study by Mosley J. et al. [14] demonstrated that anti-HBc screening would reduce the amount of HBV to be processed by virus inactivation and increase the content of anti-HBs in plasma pools in the USA.

Similarly, Souan L. et al. [15] showed the importance of screening for anti-HBc to improve blood and platelet safety in Jordan. Study carried out by Rodella A. et al. [16] reviewed the importance of the quantitative determination of anti-HBc in provision of additional information

and may be useful in the differential diagnosis of acute and chronic HBV infections and in the follow-up of chronically infected patients.

Kazakhstan is ranked as one of the countries with medium endemicity (2-7%) [17]. In 2020 about 23000 HBV cases were registered, the peak incidence was defined in West Kazakhstan, Kyzylorda region and Nur-Sultan city [18]. Approximately 21000 patients have CHB. In contrast, in Kazakhstan anti-HBcore screening for blood donors is not included.

The objective of this study was to determine the prevalence of anti-HBcore among the healthy population and the risk factors impacting positive anti-HBcore markers.

## **MATERIALS AND METHODS**

### **Study design**

A cross sectional study was conducted in 2021 in the Scientific-Production Center of Transfusiology of the Ministry of Healthcare in Kazakhstan. Consent was obtained from each prospective blood donor recruited into the study and approval was obtained from Ethics commission (Decision of EC #5 from 20 August 2020).

Participants who met the criteria as blood donors i.e., age between 18 and up, no blood donation in the last 3 months. Those who did not meet the criteria for blood donation stated in the inclusion criteria. The samples taken from blood donors were tested for anti-HBcore, by CLIA on the Architect i2000SR (ABBOTT). In case of positive anti-HBcore, the blood was further tested for anti-HBs by CLIA on the Architect i2000SR (ABBOTT) (Figure 1).

ALT were tested by kinetic method on the Biosystems A25. The presence/absence of Human immunodeficiency virus (HIV), Hepatitis B infection DNA (HBV DNA) and Hepatitis C infection were evaluated by testing, through polymerase chain reaction (PCR) techniques in pools of six samples using the Cobas TaqScreen MPX Test v.2.0 multiplex test.

### **Statistical analysis**

Statistical analysis was conducted by the R software (version 4.1.1, USA, 2021) [19]. Descriptive statistics were reported as proportions (%) for categorical variables and as means±standard deviations or medians with interquartile ranges in parentheses for continuous variables. The normality of the distribution was tested using the Kolmogorov-Smirnov test. Chi-square or Fisher's exact tests for categorical variables and Student's T-test or Mann-Whitney U test for continuous independent variables were conducted, as appropriate. Statistically significant results were considered values below  $p \leq 0.05$ .

## RESULTS

A total of 5709 participants was consecutively enrolled in this study. The sample was composed of 68.17% (3139) males and 31.83% (1466) females. The average age of the participants was  $35.69 \pm 10.57$  years ranging from 18 to 66 years. The majority of the participants were of Kazakh origin (84%).

Analysis of anamnestic data showed less than 2% of them had a family member with hepatitis in the last 6 months, and more than 1% of respondents had transfused donated blood or its components in the last 12 months (1.2%),

The prevalence of anti-HBcore among study participants was 17.2% (983). The highest prevalence of anti-HBcore was observed among the young age group 30-39 years old (Fig 2).

Participants with positive anti-HBcore scores were on average older (41.8 vs 34.4 years,  $p < 0.001$ ), Kazakh origin (88.7% vs 83.0%,  $p < 0.001$ ) participants with negative anti-HBcore results respectively (Table 1).

Among participants with elevated ALT (170), positive anti-HBcore marker was determined in 23% (39) participants (Figure 3), and in 17% (944) of donors with normal levels of ALT (5539) (Figure 4).

Our interpretation of the results was done according to World Health Organization (WHO) recommendations [20]: positive anti-HBcore marker and anti-HBs marker obtained less than 100

m-IU/ml evaluated as an estimate of discarded donations. Results of testing of anti-HBcore positive samples for the presence of antibodies of HBsAg demonstrated that, 89% (875) have anti-HBs positive markers (Fig.5). The number of donors with a titer of less than 100 m-IU/ml was 298.

## DISCUSSION

We have investigated the seroprevalence of anti-HBcore and anti-HBs among healthy population – blood donors in Kazakhstan. The prevalence of anti-HBcore among the study population was found to be 17,2%. Results of testing of anti-HBcore-positive samples for the presence of antibodies to HBsAg indicated that 89% donors have positive anti-HBs marker.

Houareau C. et al. [12] estimated 0.22% of screened donations were anti-HBcore reactive but HBsAg negative. Study conducted by Villar L. et al. [21] indicated overall prevalence of anti-HBcore and anti-HBs 14.5%, 40.9%, respectively. Anti-HBcore prevalence was positively associated with older age (41 years and above). In our study, the seroprevalence of anti-HBcore was low at the young age group, then peaked among 30-39 years old. We can assume that it might be reasoned due to the introduction of universal HBV vaccination in 1998 [22].

The prevalence of hepatitis B core antigen was 20% in Malaysia [23]. The risk of anti-HBcore seropositivity significantly increased with age and was 53% higher among males than females. Our study also revealed that HBV has more prevalence in males. However, according to the results of a study conducted in Almaty among Russians and Kazakhs, total anti-HBcore was similar in women and men [24]. 9.8% of patients were tested to be positive for anti-HBcore alone in India [25].

Ye X. et al. [26] demonstrated the rate of anti-HBcore positivity increased steadily with age, ranging from the age group younger than 30 years to the age group up to 50 years. A little over 70% of patients carried anti-HBs which is similar to our results. Younger donors with mean age of 25 years were exposed to HBV to a lesser extent compared to those with a mean age of 29 years

in study in Pakistani blood donors [27]. Results of study carried out by Muselmani W. [28] suggest including anti-HBcore as an additional screening test for blood donors in Syria to reduce the risk of HBV transmission. In Spain, the rate of anti-HBcore positive cases, HBsAg-negative carriers is approximately 10% of adults between the age of 26 and 65 years [29].

Aguia J. et al. [30] suggest some 33 to 50 percent of cases of hepatitis B that could be transmitted by transfusion of blood from HBsAg-negative donors are prevented by anti-HBcore screening [30]. In Jordan among donors, the prevalence of anti-HBcore was 6.04% [12].

Zhou J. et al. [31] demonstrated that serum anti-HBcore is significantly corrected with hepatic inflammation in CHB patients with normal ALT. In our study, a positive anti-HBcore marker was determined in 23% participants with elevated ALT, and in 17% of donors with normal levels of ALT. Before the NAT era implementation, ALT was widely used in routine practice and called to be a surrogate hepatic infection marker. Despite various updated testing algorithms, ALT value for the detection of hepatitis or any other liver inflammation in its early stage is under debates, otherwise more positive opinions than negative outcomes for clinical prove has no doubts [32-33]. This study has several strengths. The large sample size (5709 participants) allowed for higher statistical power to measure prevalence with greater precision.

Anti-HBcore prevalence in Kazakhstan (17.2%) compared to other countries (Croatia 7%, France 7%, Germany 9%, Iran 16%, Malaysia 20% respectively) remains above average. Given the prevalence of HBV, it is recommended to include an additional anti-HBcore marker in the obligatory screening algorithm of donated blood in the country and improve preventive measures for HBV transmission.

**Declaration of conflicting interests:** The authors declare that there is no conflict of interest in the present study.

**Funding.** This research was supported by a grant from Abbott Laboratories, Chicago.

**Author contribution statement:** All authors were equally involved.

## References

1. World Health Organization. Global Health Sector Strategies on Viral Hepatitis 2016-2021. 2016. p. 13. Available on [http://apps.who.int/gb/ebwha/pdf\\_files/WHA69/A69\\_32-en.pdf?ua=1](http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1)
2. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatology Int.* 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology.* 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190.
4. Khubutiya MSh, Solonin SA, Kobzeva EN, Godkov MA. The problems of providing infectious disease safety for organ and tissue donation by screening blood-borne viral infections. *Russian Journal of Transplantation and Artificial Organs.* 2016;18. 83-90. doi:10.15825/1995-1191-2016-1-83-90.
5. Torbenson M, Thomas DL. Occult hepatitis B infection. *Lancet Infect Dis* 2003; 2: 479–486.
6. Hu KQ. Occult hepatitis B virus infection and its clinical implications. *J Viral Hep* 2002; 9: 243–257.
7. Brechot C, Thiers V, Kremsdorf D, et al. P.Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’? *Hepatology.* 2001; 34: 194–203.
8. Skorikova SV, Burkitbaev ZK, Savchuk TN, et al. Prevalence and incidence of infections among blood donors in Astana. *Vopr Virusol.* 2015;60(1):34-6.
9. Debra A, Kessler RN, Alexandra Jimenez MD. In *Transfusion Medicine and Hemostasis (Third Edition)*, 2019.
10. Martelli CM, Turchi M, Souto FJ, et al. Anti-HBc testing for blood donations in areas with intermediate hepatitis B endemicity. *Rev Panam Salud Publica.* 1999 Jul;6(1):69-73. doi: 10.1590/s1020-49891999000600018.
11. Barotine-Toth K, Hoffer I. Hungarian National Blood Transfusion Service. *Transfus Med Hemother.*2006;33:415- 419. doi: 10.1159/000095119.
12. Houareau C, Offergeld R. Anti-HBc screening - is it worth the effort? Results of a 10-year surveillance programme covering more than 30 million donations in Germany. *Vox Sang.* 2019 Jul;114(5):459-466. doi: 10.1111/vox.12781.
13. an de Laar TJ, Marijt-van der Kreek T, Molenaar-de Backer MW, et al. The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country. *Transfusion.* 2015 Jun;55(6):1206-13. doi: 10.1111/trf.12962.
14. Mosley JW, Stevens CE, Aach RD, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. *Transfusion.* 1995 Jan;35(1):5-12. doi: 10.1046/j.1537-2995.1995.35195090661.x.
15. Souan L, Tout F, Siag M, et al. Seroprevalence rates of transfusion-transmitted infections among blood donors in Jordan. *J Infect Dev Ctries.* 2016 Apr 28;10(4):377-83. doi: 10.3855/jidc.8160.
16. Rodella A, Galli C, Terlenghi L, et al. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. *J Clin Virol.* 2006 Nov;37(3):206-12. doi: 10.1016/j.jcv.2006.06.011. Epub 2006 Aug 8. PMID: 16893678.
17. Konysbekova Aliya. Epidemiology aspects of the chronic HBV with HDV infection in Kazakhstan. *Eurasian Journal of Clinical Sciences.*2019; 2. 4-5. doi:10.28942/ejcs.v2i2.67.
18. Jumabayeva A, Nersesov A, Kulzhanov M, et al. Prevalence of Viral Hepatitis B, C, and D in Kazakhstan. *ScientificWorldJournal.* 2022 Apr 22;2022:9102565. doi: 10.1155/2022/9102565..



19. R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
20. World Health Organization. Screening donated blood for transfusion-transmissible infections: recommendations. 2009. p.72.
21. Villar LM, Milagres FP, Lampe E, et al. Determination of hepatitis B, C and D prevalence among urban and Amerindian populations from the Eastern Brazilian Amazon: a cross sectional study. *BMC Infect Dis*. 2018 Aug 20;18(1):411. doi: 10.1186/s12879-018-3279-2.
22. Ospanova EN, Amantay Y, Imanova DN, et al. Background of hepatitis B focal infection rise among immunized population. *Life Science Journal*. 2014;11(4):294–6.
23. Vilibic-Cavlek T et al. Prevalence of viral hepatitis in Croatian adult population undergoing routine check-up, 2010–2011. *Cent. Eur. J. Public Health*. 2014;22:29–33. doi: 10.21101/cejph.a3844.
24. Nurgalieva ZZ, Hollinger FB, Graham DY, et al. Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan. *World J Gastroenterol*. 2007 Feb 28;13(8):1204-7. doi: 10.3748/wjg.v13.i8.1204.
25. Asim M, Ali R, Khan LA, et al. Significance of anti-HBc screening of blood donors and its association with occult hepatitis B virus infection: Implications for blood transfusion. *Indian J Med Res*. 2010 Sep;132:312-7.
26. Ye X, Li T, Xu X, et al. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. *Blood Transfus*. 2017 Jan;15(1):6-12. doi: 10.2450/2016.0268-15.
27. Bhatti FA, Ullah Z, Salamat N, et al. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. *Transfusion*. 2007 Jan;47(1):74-9. doi: 10.1111/j.1537-2995.2007.01066.x.
28. Muselmani W, Habbal W, Monem F. Significance of screening antibodies to hepatitis B virus core antigen among Syrian blood donors. *Transfus Med*. 2013 Aug;23(4):265-8. doi: 10.1111/tme.12043.
29. Barcena R. Transmisión de la infección B por injertos anti-HBc positivos [Hepatitis B infection transmission by anti-HBc-positive grafts]. *Gastroenterol Hepatol*. 2014 Jul;37 Suppl 2:43-50. Spanish. doi: 10.1016/S0210-5705(14)70068-8.
30. Aguiar JI, Aguiar E, Paniago A, et al. Prevalence of Antibodies to Hepatitis B Core Antigen in Blood Donors In the Middle West Region of Brazil. 2001;96(2): 185-187.
31. Zhou J, Song L, Zhao H. et al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. *Sci Rep*. 2017;7, 2747. doi:10.1038/s41598-017-03102-3
32. Liu Z, Que S, Xu J, et al. Alanine aminotransferase-old biomarker and new concept: a review. *Int J Med Sci*. 2014 Jun 26;11(9):925-35. doi: 10.7150/ijms.8951.
33. Ikeda D, Sugawa M, Kawahara K. Study on Evaluation of Alanine Aminotransferase (ALT) as Surrogate Marker in Hepatitis Virus Test. *J Med Dent Sci*. 2016;63(2-3):45-52. doi: 10.11480/jmds.630302.




Fig 1. Algorithm for testing donors for the anti-HBcore




Fig 2. Age-specific distribution of anti-HBcore seroprevalence




Fig 3. Indicators of a-HBcore detection among donors who had elevated ALT levels




Fig 4. Indicators of a-HBcore detection among donors who had normal ALT indicators




Fig.5. Prevalence of anti-HBcore and anti-HBs markers

Table 1. Data for Descriptive Analysis

Variables	Total N=5709	anti-HBscore		p-value
		Negative	Positive	
		n=4726	n=983	
Age (mean (SD))	35.69 (10.57)	34.42 (10.33)	41.75 (9.54)	<0.001
Gender, n (%)				0.46
Females	1466 (31.8)	1220 (32.1)	246 (30.7)	
Males	3139 (68.2)	2583 (67.9)	556 (69.3)	
Ethnicity, n (%)				<0.001
Kazakh	3855 (84.0)	3146 (83.0)	709 (88.7)	
Russian	415 (9.0)	364 (9.6)	51 (6.4)	
Other ethnicities	320 (7.0)	281 (7.4)	39 (4.9)	
Have family members had hepatitis in the last 6 months? n (%)				0.41
Yes	68 (1.6)	59 (1.7)	9 (1.2)	
Not	4096 (98.4)	3367 (98.3)	729 (98.8)	
Having transfusion of donated blood or its components in the last 12 months, n (%)				0.57
Yes	56 (1.2)	44 (1.1)	12 (1.4)	
Not	4653 (98.8)	3835 (98.9)	818 (98.6)	
Having intravenous or intramuscular injections, acupuncture, tattoos or piercings in the last 4 months				0.71
Yes	247 (5.2)	201 (5.2)	46 (5.6)	
Not	4458 (94.8)	3678 (94.8)	780 (94.4)	
Having surgical interventions (including cosmetic surgery or organ removal), n (%)				0.18
Yes	722 (15.3)	608 (15.7)	114 (13.7)	
Not	3989 (84.7)	3273 (84.3)	716 (86.3)	

Missing answers: for gender - 1104 (19.3%); for ethnicity - 1119 (19.6%), for family history of hepatitis – 1545 (27.1%), for blood transfusions – 1000 (17.5%), for Intravenous or intramuscular injections, acupuncture, tattoos or piercings – 1004 (17.6%), for surgical interventions – 998 (17.5%)